Acceleron Pharma (XLRN) Misses Q4 EPS Expectations

Acceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.81), $0.72 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $15.7 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c